FDA Expands Indication for PCSK9 Alirocumab (Praluent) FDA Expands Indication for PCSK9 Alirocumab (Praluent)
The decision allows the cholesterol-lowering drug to be prescribed to reduce the risk for major cardiovascular events, including myocardial infarction and stroke.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Cardiology News Source Type: news
More News: Brain | Cardiology | Cardiovascular | Cholesterol | Heart | Heart Attack | Neurology | Neurosurgery | Stroke